The Technical Analyst
Select Language :
Catabasis Pharmaceuticals [CATB]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Catabasis Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Catabasis Pharmaceuticals is listed at the  Exchange

-6.97% $8.54

America/New_York / 9 sep 2021 @ 00:00


Catabasis Pharmaceuticals: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 234.86 mill
EPS: 0
P/E: 0
Earnings Date: N/A
SharesOutstanding: 27.50 mill
Avg Daily Volume: 0.529 mill
RATING 2021-09-10
B+
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Sell
Price To Book: Neutral
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 0 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
N/A
Company: PE 0 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 8.44 - 8.65

( +/- 1.23%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2021-06-08 Harshbarger Benjamin Buy 200 000 Stock Option (right to buy)
2021-06-02 Callori Fred Buy 85 000 Stock Option (right to buy)
2021-06-02 Violin Jonathan Buy 85 000 Stock Option (right to buy)
2021-06-02 Clauser Noah Buy 600 000 Stock Option (right to buy)
2021-06-02 Kishbauch Michael D Buy 100 000 Stock Option (right to buy)
INSIDER POWER
0.00
Last 86 transactions
Buy: 7 288 895 | Sell: 328 827

Forecast: 01:40 - $5.00

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $8.54 (-6.97% )
Volume 0.0989 mill
Avg. Vol. 0.529 mill
% of Avg. Vol 18.69 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Catabasis Pharmaceuticals Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Catabasis Pharmaceuticals Inc

RSI

Intraday RSI14 chart for Catabasis Pharmaceuticals Inc

Last 10 Buy & Sell Signals For CATB

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Catabasis Pharmaceuticals Inc

CATB

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.

Last 10 Buy Signals

Date Signal @
YAKUSDMar 28 - 07:33839.25
^N100Mar 28 - 07:22PTS1 528.40
RNDRUSDMar 28 - 07:3411.36
XCHUSDMar 28 - 07:31$41.54
^FCHIMar 28 - 07:18PTS8 235.70
PENDLEUSDMar 28 - 07:284.12
KCSUSDMar 28 - 07:19$12.09
DIGGUSDMar 28 - 07:19914.30
ETHXUSDMar 28 - 07:183 584.83
CTXUSDMar 28 - 07:194.55

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.